Nanosynex

Company Overview

Snapshot

Founded in February 2017 by Diane Abensur and Michelle Heymann, Nanosynex operates with 1–10 employees. The company has raised $6.34 million across seven funding rounds. In June 2025, Nanosynex received a grant from Synergy7 and Israel Innovation Authority, signaling continued support for its diagnostic solutions.

Business overview

Nanosynex develops solutions to enhance testing quality and reduce healthcare costs by accelerating diagnostic processes. The company's core product is an innovative antimicrobial susceptibility test (AST) that utilizes a phenotypic approach and a microfluidic disposable test cartridge platform. This solution, comprising a disposable test platform, hardware, and analysis software, enables laboratories to perform and provide same-day AST results. This allows doctors to create targeted, personalized antibiotic prescriptions for patients, addressing the critical need for rapid and effective treatment in the face of antibiotic resistance. Nanosynex operates within the Health Tech & Life Sciences sector, specifically focusing on Digital Healthcare, Digital Medical Diagnostics, and Medical Decision Support, serving laboratories and healthcare providers.

Strategic signal

In January 2021, Nanosynex announced its intention to bring rapid COVID-19 tests to Israel. This move indicates the company's agility in adapting its diagnostic expertise to address urgent public health needs beyond its core antimicrobial susceptibility testing, signaling its potential for broader impact in the diagnostics market and its capability to respond to emerging health crises.

Company Intelligence Q&A

What is Nanosynex's primary focus?

Nanosynex is focused on developing and commercializing an innovative antimicrobial susceptibility test (AST) that provides rapid, same-day results. This technology aims to improve testing quality and reduce healthcare costs by enabling targeted, personalized antibiotic prescriptions.

When was Nanosynex founded and by whom?

Nanosynex was founded in February 2017 by Diane Abensur and Michelle Heymann.

What significant grant did Nanosynex receive in June 2025?

In June 2025, Nanosynex received a grant from Synergy7 and Israel Innovation Authority. This funding supports the development of its diagnostic solutions.

What was a key strategic development for Nanosynex in October 2020?

In October 2020, Nanosynex received a €2.6 million grant from the European Commission's Horizon 2020 program to support the development of its prototype and entry into the European market by 2023 for its rapid antibiotic susceptibility testing platform.

What partnership did Nanosynex establish in February 2020?

In February 2020, Nanosynex partnered with French medical diagnostics company Biosynex for the distribution of its diagnostic device in over sixty countries, aiming to combat antibiotic resistance.